ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2

Apr 08, 2021

ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors

Apr 01, 2021

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer

Mar 29, 2021

ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors

Mar 22, 2021

ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations

Mar 15, 2021

ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses

Mar 11, 2021

ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company

Mar 10, 2021

ImmunityBio and NantKwest Complete Merger

Mar 09, 2021

Stockholders of NantKwest Approve Merger With ImmunityBio

Mar 08, 2021

ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

Mar 08, 2021